Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

@article{Group1994RandomisedTO,
  title={Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)},
  author={Scandinavian Simvastatin Survival Study Group},
  journal={The Lancet},
  year={1994},
  volume={344},
  pages={1383-1389}
}

Figures and Tables from this paper

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
TLDR
The analyses suggest that the beneficial effect of simvastatin in individual patients in 4S was determined mainly by the magnitude of the change in LDL cholesterol, and they are consistent with current guidelines that emphasize aggressive reduction of this lipid in CHD patients.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
TLDR
Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Cost-effectiveness of statins for coronary heart disease patients with hypercholesterolaemia
TLDR
Subsequent large clinical trials such as the Cholesterol And Recurrent Events (CARE) Trial and Long-term Intervention with Pravastatin In Ischaemic Disease (LIPID) study, showed that lower-risk patients also benefited from statins.
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).
TLDR
Nondiabetic CHD patients with or without the metabolic syndrome realize a similar, substantial relative reduction in the risk of cardiovascular events, and the absolute benefit may be greater in patients with the metabolic Syndrome because they are at a higher absolute risk.
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
TLDR
Treatment with pravastatin over 5 years reduces all-cause mortality and coronary mortality in patients with and those without a history of coronary heart disease, and the size of the benefit was related principally to the baseline risk.
Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.
TLDR
The lipid lowering effect and safety of the low-dose simvastatin therapy used in the J-LIT study, a nationwide cohort study utilizing the clinical practice of general physicians, and the low incidence of drug-related adverse events in this study may be also related to the low dosage of simVastatin.
A Prospective, Randomized, Double-Blind, Placebo- Controlled Clinical Trial of Simvastatin in Non-Ischemic Heart Failure: The Simvastatin in Non-Ischemic Heart Failure (SNIHF) Study Group
TLDR
The use of statins for novel indications other than the lowering of cholesterol and the primary and secondary prevention of coronary artery disease are currently being investigated, and one potential novel application for statin therapy is in the treatment of congestive heart failure.
...
...

References

SHOWING 1-10 OF 45 REFERENCES
Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.
TLDR
The simvastatin regimens studied produced large sustained reductions in total cholesterol, LDL cholesterol and triglyceride and small increases in HDL cholesterol and were well tolerated, with no evidence of serious side-effects during the first 3 years of this study.
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
TLDR
In men and women with moderately elevated LDL cholesterol, lovastatin reverses progression of IMT in the carotid arteries and appears to reduce the risk of major cardiovascular events and mortality.
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
TLDR
The association between reduction of cholesterol concentrations and deaths not related to illness warrants further investigation and the failure of cholesterol lowering to affect overall survival justifies a more cautious appraisal of the probable benefits of reducing cholesterol concentrations in the general population.
The Oslo Diet‐Heart Study: Eleven‐Year Report
TLDR
The study deals with 412 men, aged 30 to 64 years, randomized 1 to 2 years after a first myocardial infarction, and found major coronary heart disease relapses, including fatal and nonfatal events (MI), were significantly reduced.
Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
TLDR
Significant evidence is provided supporting the beneficial effects of lipid modification in the reduction of atherosclerosis progression and sustained improvement in the blood lipid patterns of patients who have had a myocardial infarction and reduces their subsequent morbidity due to coronary heart disease.
Doubts about preventing coronary heart disease.
TLDR
The latest report of a trial aimed at preventing coronary heart disease in middle aged men in Finland found that over the 10 years after the trial ended cardiac deaths and total mortality progressively increased in the intervention group compared with the controls, the first report of increased mortality from coronaryHeart disease after multifactorial intervention.
Should there be a moratorium on the use of cholesterol lowering drugs?
TLDR
An aggressive approach to cholesterol reduction features in most of the official guidelines for the primary prevention of coronary heart disease, and high percentages of the British population would become candidates for drug treatment if the guidelines currently advanced by some authorities were put into practice.
...
...